Test bank for Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics, 8th Edition by Nader Rifai, PhD Chapters 1 - 49  

Test bank for Tietz Fundamentals of Clinical Chemistry
and Molecular Diagnostics,
8th Edition by Nader Rifai, PhD
Chapters 1 - 49

,Tietzl2Fundamentalsl2ofl2Clinicall2Chemistryl2andl2Molecularl2Diagnosticsl28thl 2 Editionl2Testl2Bank

Tablel2ofl2contents:
I.l2Principlesl2Ofl2Laboratoryl2Medicine
Chapterl21.l2Clinicall2Chemistry,l2Molecularl2Diagnostics,l2andl2Laboratoryl2Medicine
Chapterl22.l2Selectionl2andl2Analyticall2Evaluationl2ofl2Methodsl2—l2Withl2Statisticall2Techniques
Chapterl23.l2Clinicall2Evaluationl2ofl2Methods
Chapterl24.l2Evidence-Basedl2Laboratoryl2Medicine
Chapterl25.l2Establishmentl2andl2Usel2ofl2Referencel2Values
Chapterl26.l2Specimenl2Collection,l2Processing,l2andl2Otherl2Preanalyticall2Variables
Chapterl27.l2Qualityl2Management
II.l2Analyticall2Techniquesl2Andl2Instrumentation
Chapterl28.l2Principlesl2ofl2Basicl2Techniquesl2andl2Laboratoryl2Safety
Chapterl29.l2Opticall2Techniques
Chapterl210.l2Electrochemistryl2andl2Chemicall2Sensors
Chapterl211.l2Electrophoresis
Chapterl212.l2Chromatography
Chapterl213.l2Massl2Spectrometry
Chapterl214.l2Enzymel2andl2Ratel2Analyses
Chapterl215.l2Immunochemicall2Techniques
Chapterl216l2Automation
Chapterl217.l2Point-of-Carel2Instrumentation
III.l 2 Analytes
Chapterl218.l2Aminol2Acids,l2Peptides,l2andl2Proteins
Chapterl219.l2Seruml2Enzymes
Chapterl220.l2Tumorl2Markersl2andl2Cancerl2Genes
Chapterl221.l2Kidneyl2Functionl2Testsl2—l2Creatinine,l2GFR,l2Urea,l2andl2Uricl2Acid
Chapterl222.l2Carbohydrates
Chapterl223.l2Lipids,l2Lipoproteins,l2Apolipoproteins,l2andl2Otherl2Cardiacl2Riskl2Factors
Chapterl224.l2Electrolytesl2andl2Bloodl2Gases
Chapterl225.l2Hormones
Chapterl226.l 2 Catecholaminesl2andl2Serotonin
Chapterl227.l 2 Vitamins,l2Tracel2Elements,l2Nutritionall2Assessment
Chapterl228.l2Hemoglobin,l2Iron,l2andl2Bilirubin
Chapterl229.l2Porphyrinsl2andl2Porphyrias
Chapterl230.l2Therapeuticl2Drugsl2andl2Theirl2Management
Chapterl231.l2Clinicall2Toxicology
Chapterl232.l 2 Toxicl2Metals
IV.l 2 Pathophysiology
Chapterl233.l2Diabetes

,Chapterl234.l 2 Cardiovascularl2Disease
Chapterl235.l2Kidneyl2Disease
Chapterl236.l 2 Physiologyl2andl2Disordersl2ofl2Water,l2Electrolyte,l2andl2Acid-Basel2Metabolism
Chapterl237.l2l2Liverl2Disease
Chapterl238.l 2 Gastrointestinall2andl2Pancreaticl2Diseases
Chapterl239.l2l2Disordersl2ofl2Bonel2andl2Minerall2Metabolism
Chapterl240.l2l2Disordersl2ofl2thel2Pituitaryl2Gland
Chapterl241.l 2 Disordersl2ofl2thel2Adrenall2Cortex
Chapterl242.l 2 Thyroidl2Disorders
Chapterl243.l 2 Reproduction-Relatedl2Disorders
Chapterl244.l2l2Pregnancyl2andl2Prenatall2Testing
Chapterl245.l 2 Newbornl2Screeningl2andl2Inbornl2Errorsl2ofl2Metabolism
Chapterl246.l2Pharmacogenetics
V.l 2 Molecularl2Diagnostics
Chapterl247.l2Principlesl2ofl2Molecularl2Biology
Chapterl248.l2Nucleicl2Acidl2Techniquesl2andl2Applications
Chapterl249.l2Genomesl2andl2Nucleicl2Acidl2Alterations

, Chapterl201:l2Clinicall2Chemistry,l2Molecularl2Diagnostics,l2andl2Laboratoryl2Medicinel2Test2lB
ank


MULTIPLEl2CHOICE

1. Anl2individuall2workingl2inl2al2clinicall2chemistryl2laboratoryl2isl2marriedl2tol2al2salesl2representa
tivel2whol2worksl2forl2al2companyl2thatl2sellsl2chemistryl2laboratoryl2supplies.l2Whenl2thel2labor
atoryl2managerl2requestsl2al2listl2ofl2neededl2supplies,l2costl2ofl2supplies,l2andl2vendors,l2thisl2in
dividuall2onlyl2recommendsl2thel2spouse’sl2companyl2asl2thel2vendor.l2Thisl2isl2consideredl2tol2be
l2a(n):

a. accountingl2issue.
b. possiblel2conflictl2ofl2interest.
c. maintenancel2ofl2confidentialityl2issue.
d. probleml2withl2resourcel2allocation.

ANS:l 2 B
Concernl2hasl2beenl2raisedl2overl2thel2interrelationshipsl2betweenl2practitionersl2inl2thel2medic
all2fieldl2andl2commerciall2suppliersl2ofl2drugs,l2devices,l2equipment,l2etc.,l2tol2thel2medicall2prof
ession.
Similarly,l2relationshipsl2havel2beenl2scrutinizedl2betweenl2clinicall2laboratoriansl2andl2manufac
turersl2andl2providersl2ofl2diagnosticl2equipmentl2andl2supplies.l2Thesel2concernsl2ledl2thel2Natio
nall2Institutesl2ofl2Healthl2(NIH)l2inl21995l2tol2requirel2officiall2institutionall2reviewl2ofl2financiall2d
isclosurel2byl2researchersl2andl2managementl2ofl2situationsl2inl2whichl2disclosurel2indicatesl2pote
ntiall2conflictsl2ofl2interest.

DIF: 1 REF:l2l2l2Pagel24-5 OBJ:l 2 6l2|l27

2. Al2patientl2visitsl2herl2physicianl2statingl2thatl2herl2prescribedl2painkillerl2isl2notl2workingl2tol2r
educel2thel2painl2followingl2herl2recentl2surgery.l2Al2friendl2ofl2thel2patientl2claimsl2thatl2thel2sa
mel2painkillerl2“workedl2wonders”l2tol2reducel2herl2painl2afterl2thel2samel2surgery.l2Thel2physic
ianl2statesl2thatl2thel2differencel2inl2thel2effectl2ofl2thel2drugl2mightl2bel2causedl2by
,l2whichl2isl2studiedl2inl2pharmacogenetics.
a. epidemiology
b. anl2inheritedl2disease
c. al2conflictl2ofl2interest
d. al2geneticl2variationl2inl2drug-metabolizingl2enzymes
ANS:l 2 D
Pharmacogeneticsl2isl2thel2studyl2ofl2thel2geneticl2variationl2ofl2drugl2metabolisml2bet
weenl2individuals.

DIF: 1 REF:l2l2l2Pagel23 OBJ:l 2 1

3. Johnl2worksl2inl2al2molecularl2diagnosticsl2laboratoryl2andl2receivesl2al2bloodl2samplel2thatl2ha
sl2thel2namel2ofl2al2closel2friendl2printedl2onl2thel2bar-
codedl2label.l2Thel2geneticl2testl2thatl2isl2orderedl2onl2thel2friend’sl2samplel2wouldl2providel2dia
gnosticl2informationl2aboutl2al2disorderl2thatl2hasl2al2poorl2prognosis,l2andl2thel2testl2isl2usuall
yl2performedl2byl2John.l2Hel2asksl2al2fellowl2employeel2tol2analyzel2thel2samplel2forl2himl2andl2n
otl2divulgel2thel2results.l2Thisl2ethicall2issuel2concerns:
a. confidentialityl2ofl2patientl2geneticl2andl2medicall2information.
b. al2conflictl2ofl2interest.
c. resourcel2allocation.